Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Phase 2 Terminated

142 enrolled 13 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Clinical Trials

Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Impact of Early Mobility on Post-Surgery Recovery in Patients Undergoing Oncologic Surgeries

Quality Improvement of Patient-Provider Communication For Colorectal Cancer Screening

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma